Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan | Synapse
February 13, 2026Intestinal Research0 citationsOpen Access
Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan
To assess the efficacy and safety of mirikizumab as a maintenance therapy for ulcerative colitis in patients with difficult-to-treat inflammatory bowel disease.
Conducted a single-center retrospective review of patients
Focused on maintenance therapy with mirikizumab
Collected and analyzed real-world treatment data
Demonstrated promising efficacy of mirikizumab in maintaining remission
Highlighted a favorable safety profile among treated patients
Provided supporting data for the use of mirikizumab in difficult-to-treat cases
Abstract
The present study demonstrated real-world data regarding maintenance therapy with mirikizumab for UC among patients with DTT-IBD.